Treatment-free remission (TFR) is feasible after 2 or more years of frontline nilotinib treatment in patients with chronic myeloid leukemia in chronic phase (CML-CP), reported researchers in a study published in Leukemia. Advances in the treatment of CML have improved outcomes for those with the disease; however, long-term treatment with tyrosine...
Latest News
Treatment-free remission (TFR) is feasible after 2 or more years of frontline nilotinib treatment in patients with chronic myeloid leukemia in chronic phase (CML-CP), reported researchers in a study published in Leukemia. Advances in the treatment of CML have improved outcomes for those with the disease; however, long-term treatment with tyrosine...
Memphis, Tenn – Compared to adult cancers, pediatric cancers often have distinctive genetic causes. This means there is an opportunity to develop pediatric-focused diagnostic strategies and treatments. Research by St. Jude Children’s Research Hospital published today in Nature Genetics clarifies the genomic landscape of pediatric acute myeloid leukemia (pAML). The...
A Kidney Disease: Improving Global Outcomes (KDIGO) committee has released a new 2021 clinical practice guideline that updates their 2012 recommendations for the management of lupus nephritis (LN) and other glomerular diseases. The new guideline presents recommendations and practice points on various glomerular diseases, including LN, IgA nephropathy and IgA...
ZURICH, Switzerland – Antiphospholipid syndrome is a systemic autoimmune disease associated with persistent antiphospholipid antibodies (aPL). It can cause thrombosis and pregnancy complications as well as non-thrombotic manifestations such as cardiac valve disease. Classification is important to help identify people to take part in research and ensures that similar disease...
DUBLIN – Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its strategic partner Mitsubishi Tanabe Pharma Corporation (MTPC) has received manufacturing and marketing approval of UPLIZNA for the prevention of relapses of neuromyelitis optica spectrum disorder (including neuromyelitis optica) from the Japanese Ministry of Health, Labour and Welfare. MTPC has rights to the development...
According to a report published in Blood, addition of the novel E-selectin inhibitor uproleselan to both an intensive chemotherapy-based salvage regimen and a standard intensive frontline regimen was safe, well tolerated, and active in patients with acute myeloid leukemia (AML). Expression of E-selectin in the bone marrow microenvironment contributes to drug...
Göttingen, Germany – In individuals with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), uric acid (UA) metabolism might be involved in activation of the complement system and thus serve as a contributory factor in the disease course, according to findings from a retrospective study published in the International Journal of Molecular...
PRINCETON, N.J. — UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced a licensing agreement with MEDAC GmbH to develop a next-generation novel mitomycin-based formulation for urothelial cancers. UGN-103, UroGen’s RTGel® technology combined with medac’s licensed mitomycin, is a...
Minnesota nice is being proven all over again. A young man from Africa says he is proof of that as doctors in St. Paul rebuild not only his face but his entire future. Even for skilled specialists, the surgical case on the table before them is a challenge. “It’s kind...